← Leaderboards
Zheng Jiang
Baylor College Of Medicine
$1,884,061
Attributed
$2,168,122
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $968.1K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,168,122 · 2
By mechanism
R01$2,168,122 · 2
Top collaborators
- Wei Li1 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Nicholas P Poolos$6,654,849
- Ross Anthony Poche$9,387,509
- Helen S Cohen$6,559,003
- Robert M Bryan$13,758,172
- Theodore G Wensel$33,336,270
Others in their field
Other Rising Stars on “Retinal Ganglion Cells”
- Philip Raymond Williams · Boston Children'S Hospital$2,762,442
- Benjamin J. Kim · University Of Pennsylvania$2,126,420
- Shane Liddelow · New York University School Of Medicine$2,023,416
- Sasan Moghimi Araghi · University Of California, San Diego$1,984,890
- Kenneth Schultz · Trethera Corporation$1,606,501
- Susana Isabel M M A Da Silva · University Of Pittsburgh At Pittsburgh$1,577,955
Research focus
Retinal Ganglion CellsCell DeathRetinal DiseasesRetinal NeuronInnovationCellsLightRetinaSignal TransductionBlindnessResponseOverexpressionAnimalsImmunocytochemistryBrainImageInflammatory ResponseIon ChannelFutureCyclic-Nucleotide Gated Ion ChannelsFamilyCyclic NucleotidesDeath RateFos Gene
Grant awards (5)
The role of vascular ligands and neurovascular dysfunction in glaucoma and therapeutic potential$568,122
R01 · FY2025 · EY
A new strategy for vision restoration based on melanopsin transduction mechanisms$400,000
R01 · FY2025 · EY · contact PI
A new strategy for vision restoration based on melanopsin transduction mechanisms$400,000
R01 · FY2024 · EY · contact PI
A new strategy for vision restoration based on melanopsin transduction mechanisms$400,000
R01 · FY2023 · EY · contact PI
A new strategy for vision restoration based on melanopsin transduction mechanisms$400,000
R01 · FY2022 · EY · contact PI